ArticleMetabolomics : Official journal of the Metabolomic Society2018
A review of metabolism-associated biomarkers in lung cancer diagnosis and treatment.
Article in Metabolomics : Official journal of the Metabolomic Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 99 citations in OpenAlex.
- In Vitro Cytotoxic Activity ofMolecules (Basel, Switzerland) · 2026Article
- Biomarkers of Cancer Metabolism and Therapeutic Response.Cancer treatment and research · 2026Review
- MULGONET: An interpretable neural network framework to integrate multi-omics data for cancer recurrence prediction and biomarker discovery.Fundamental research · 2026Article
- Global research dynamics in metabolic biomarkers and cancer: a bibliometric study from 2015 to 2025.Discover oncology · 2025Review
- Biomarkers for the diagnosis of indeterminate pulmonary nodules: are we there yet?Journal of thoracic disease · 2025Review
- Mitochondrial transplantation sensitizes chemotherapy to inhibit tumor development by enhancing anti-tumor immunity.Cancer biology & medicine · 2025Article
- Characterizing Plasma-Based Metabolomic Signatures for Metastasis in Non-Small Cell Lung Cancer.Metabolites · 2025Article
- M-GNN: A Graph Neural Network Framework for Lung Cancer Detection Using Metabolomics and Heterogeneous Graph Modeling.International journal of molecular sciences · 2025Article
- Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection.International journal of molecular sciences · 2025Article
- The prowess of metabolomics in cancer research: current trends, challenges and future perspectives.Molecular and cellular biochemistry · 2025Review
- Minimally invasive biomarkers for triaging lung nodules-challenges and future perspectives.Cancer metastasis reviews · 2025Review
- Integrative multi-omics analysis of the microbiome and metabolome in bronchoalveolar lavage fluid from patients with early-stage lung cancer.Frontiers in cellular and infection microbiology · 2025Article
- Multi-omics model is an effective means to diagnose benign and malignant pulmonary nodules.Clinics (Sao Paulo, Brazil) · 2025Article
- Article
- Article
- HCMMD: systematic evaluation of metabolites in body fluids as liquid biopsy biomarker for human cancers.Aging · 2024Review
- Metabolomics Analysis and Diagnosis of Lung Cancer: Insights from Diverse Sample Types.International journal of medical sciences · 2024Review
- Impact of Different Treatment Regimens and Timeframes in the Plasmatic Metabolic Profiling of Patients with Lung Adenocarcinoma.Metabolites · 2023Article
- Untangling the web of glioblastoma treatment resistance using a multi-omic and multidisciplinary approach.The American journal of the medical sciences · 2023Review
- An epidemiological introduction to human metabolomic investigations.Trends in endocrinology and metabolism: TEM · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
introductionLung cancer continues to be the leading cause of cancer-related mortality worldwide. Early detection has proven essential to extend survival. Genomic and proteomic advances have provided impetus to the effort dedicated to detect and diagnose the disease at an earlier stage. Recently, the study of metabolites associated with tumor formation and progression has inaugurated the era of cancer metabolomics to aid in this effort.
objectivesThis review summarizes recent work regarding novel metabolites with the potential to serve as biomarkers for early lung tumor detection, evaluation of disease progression, and prediction of patient outcomes.
methodWe compare the metabolite profiling of cancer patients with that of healthy individuals, and the metabolites identified in tissue and biofluid samples and their usefulness as lung cancer biomarkers. We discuss metabolite alterations in tumor versus paired non-tumor lung tissues, as well as metabolite alterations in different stages of lung cancers and their usefulness as indicators of disease progression and overall survival. We evaluate metabolite dysregulation in different types of lung cancers, and those associated with lung cancer versus other lung diseases. We also examine metabolite differences between lung cancer patients and smokers/risk-factor individuals.
resultAlthough an extensive list of metabolites has been evaluated to distinguish between these cases, refinement of methods is further required for adequate patient diagnosis.
conclusionWe conclude that with technological advancement, metabolomics may be able to replace more invasive and costly diagnostic procedures while also providing the means to more effectively tailor treatment to patient-specific tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.